Oppenheimer Raises Price Target on Protalix BioTherapeutics (PLX)
Research analysts at Oppenheimer (NYSE: OPY) increased their target price on shares of Protalix BioTherapeutics (NYSE: PLX) from $9.00 to $11.00 in a report released on Wednesday. The firm currently has an “outperform” rating on the stock.
Protalix BioTherapeutics opened at 7.01 on Wednesday. Protalix BioTherapeutics has a 1-year low of $4.06 and a 1-year high of $7.70. The company’s market cap is $636.6 million.
A number of other analysts have also recently weighed in on PLX. Analysts at Canaccord Genuity downgraded shares of Protalix BioTherapeutics from a “buy” rating to a “hold” rating in a research note to investors on Wednesday. They now have a $8.00 price target on the stock. Separately, analysts at Auriga downgraded shares of Protalix BioTherapeutics from a “buy” rating to a “hold” rating in a research note to investors on Monday. They now have a $8.00 price target on the stock.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on the ProCellEx protein expression system (ProCellEx).